News
21h
GlobalData on MSNFDA grants 510(k) clearance for Tempus AI’s ejection fraction softwareThe US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...
15hon MSN
Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...
Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...
The new Tempus software analyzes resting, non-ambulatory 12-lead ECG recordings to detect signs associated with having a low ...
The White House says President Trump underwent a medical exam because of swelling in his legs and has been diagnosed with a ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...
NewYork-Presbyterian researchers have developed a deep learning model that increases doctors' abilities to diagnose ...
The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...
Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...
1d
Zacks Investment Research on MSNBAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...
Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...
3d
MedPage Today on MSNFinerenone Gets Expanded FDA Approval in Heart FailureThe FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results